Improving cervical cancer screening using a new CRISPR-based technology
Composing CODAs to cervical cancer screening through an integrated CRISPR and fluorescent nucleic acid approach
This study is testing a new, easy-to-use technology that helps doctors quickly check for cervical cancer in women in Uganda and Ghana, aiming to improve screening in places where it's really needed.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10870008 on NIH RePORTER |
What this research studies
This research aims to enhance cervical cancer screening in low-and-middle-income countries, particularly in sub-Saharan Africa, where screening rates are alarmingly low. The team has developed a novel technology called CRISPR Optical Detection of Anisotropy (CODA), which combines gene editing techniques with fluorescence to quickly and accurately detect cervical cancer markers. The method is designed to be user-friendly and can provide results in under 30 minutes, making it suitable for point-of-care settings. The project will focus on implementing this technology in Uganda and Ghana, ensuring that local healthcare providers can effectively use it.
Who could benefit from this research
Good fit: Ideal candidates for this research are women living in sub-Saharan Africa who are eligible for cervical cancer screening.
Not a fit: Patients outside of sub-Saharan Africa or those who are not eligible for cervical cancer screening may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly increase cervical cancer screening rates and early detection, ultimately saving lives.
How similar studies have performed: Previous research has shown promise in using CRISPR technology for diagnostic purposes, indicating potential success for this novel approach.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Castro, Cesar M — Massachusetts General Hospital
- Study coordinator: Castro, Cesar M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.